Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 324

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 324
---
 are available to the public on a website maintained by the SEC located at www.sec.gov.We also maintain a website at www.cero.bio/investors.Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. Information contained on our website is not a part of or incorporated by reference into this prospectus and the inclusion of our website and investor relations website addresses in this prospectus is an inactive textual reference only. 191 INDEX TO FINANCIAL STATEMENTS CERO THERAPEUTICS HOLDINGS, INC.

| Unaudited Financial Statements as of September 30, 2025 and December 31, 2024                                                                                                                                                                                                           
 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024                                                                                                                                                                                                    |     | F-2         |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:------------|
| Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2025 and 2024 (Successor), Period from February 14, 2024 through September 30, 2024 (Successor), and January 1, 2024 through February 13, 2024 (Predecessor)                                   |     | F-3         |
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the nine months ended September 30, 2025 (Successor), Periods from February 14, 2024 through September 30, 2024 (Successor), and January 1, 2024 through February 13, 2024 (Predecessor) |     | F-4         |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Successor), Period from February 14, 2024 through September 30, 2024 (Successor), and January 1, 2024 through February 13, 2024 (Predecessor)                                    |     | F-6         |
| Notes to Condensed Consolidated Financial Statements (Unaudited)                                                                                                                                                                                                                        |     | F-7 to F-34 |

| Audited